Long-term treatment with senolytic drugs Dasatinib and Quercetin ameliorates age-dependent intervertebral disc degeneration in mice.
Novais EJ, Tran VA, Johnston SN, Darris KR, Roupas AJ, Sessions GA, Shapiro IM, Diekman BO, Risbud MV. · 2021
Read Long-term treatment with senolytic drugs Dasatinib and Quercetin ameliorates age-dependent intervertebral disc degeneration in mice. by Novais EJ, Tran VA, Johnston SN, Darris KR, Roupas AJ, Sessions GA, Shapiro IM, Diekman BO, Risbud MV. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8417260.txt.
Introduction
Novais and co-authors test whether senolytic drugs can slow age-linked disc degeneration in mice. Worn spinal discs are common in older people and a leading cause of chronic back pain. Since cell senescence tracks with disc decay, the team tried the dasatinib and quercetin pair.
Mice began treatment at 6, 14, or 18 months of age and were checked at 23 months. The two younger groups showed less degeneration. Senescence markers and inflammatory signals fell in treated discs. The treatment also kept disc cells alive and preserved tissue structure. Gene activity shifts pointed to cell death and cytokine paths. The authors see senolytics as a hopeful path.
Catalog record
| CREATOR | Novais EJ, Tran VA, Johnston SN, Darris KR, Roupas AJ, Sessions GA, Shapiro IM, Diekman BO, Risbud MV. |
|---|---|
| YEAR | 2021 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 78 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Long-term treatment with senolytic drugs Dasatinib and Quercetin ameliorates age-dependent intervertebral disc degeneration in mice By Emanuel J. Novais, Victoria A. Tran, Shira N. Johnston, Kayla R. Darris, Alex J. Roupas, Garrett A. Sessions, Irving M. Shapiro, Brian O. Diekman, Makarand V. Risbud Published in: Nature Communications DOI: 10.1038/s41467-021-25453-2 ABSTRACT Intervertebral disc degeneration is highly prevalent within the elderly population and is a leading cause of chronic back pain and disability. Due to the link between disc degeneration and senescence, we explored the ability of the Dasatinib and Quercetin drug combination (D + Q) to prevent an age-dependent progression of disc degeneration in mice. We treated C57BL/6 mice beginning at 6, 14, and 18 months of age, and analyzed them at 23 months of age. Interestingly, 6- and 14-month D + Q cohorts show lower incidences of degeneration, and the treatment results in a significant decrease in senescence markers p16INK4a, p19ARF, and SASP molecules IL-6 and MMP13. Treatment also preserves cell viability, phenotype, and matrix content. Although transcriptomic analysis shows disc compartment-specific effects of the treatment, cell death and cytokine response pathways are commonly modulated across tissue types. Results suggest that senolytics may provide an attractive strategy to mitigating age-dependent disc degeneration. INTRODUCTION The prevalence and impact of age-dependent diseases is increasing with increased human lifespan. In a recent global survey of 50 chronic pathological conditions, low back pain (LBP) and neck pain ranked the 1st and 4th top causes of years lived with disability1. Although the etiology of LBP is multifactorial, intervertebral disc degeneration is regarded as a major contributor to this pathology2. Importantly, aging exacerbates disc degeneration and disease progression, giving rise to an urgent need to understand the underlying mechanisms of disc aging and develop solutions to delay or ameliorate the progression of age-dependent degeneration2,3. The intervertebral disc confers flexibility and plays a key role in accommodating the mechanical loads applied to the spinal column. These functional properties are enabled by the interaction of three unique disc compartments: the central nucleus pulposus (NP)—an avascular tissue, rich in aggrecan; the circumferential, ligamentous annulus fibrous (AF)—primarily composed of collagen fibers; and the cartilaginous endplates (CEP) bordering the NP and AF on cranial and caudal surfaces. It is now recognized that abnormal function of any of these compartments can influence degeneration of the others3,4. Defining features of disc degeneration include decreased abundance and quality of extracellular matrix (ECM), loss of biomechanical properties, an increase in inflammatory mediators and catabolic processes, and changes in cell phenotype and death5–7. Despite widespread prevalence and disease burden, no disease-modifying treatments are currently available for disc degeneration and associated pathologies. Studies of human tissues and mouse models have shown an increased incidence of senescent cells during intervertebral disc aging and degeneration8–11. Senescent cells are broadly characterized by cell cycle arrest, apoptotic-resistance, and the production of catabolic factors known as the senescence-associated secretory phenotype (SASP)12,13. Senescence can be induced in response to a variety of stimuli, including telomere attrition, oncogenes, and cell stress (e.g., oxidative, genotoxic, cytokines), which can contribute to SASP activation and senescence transformation12,13. Increased expression of cell cycle inhibitors p21, p53, and p16INK4a are responsible for maintaining the stable arrest of senescence. Alterations to cell division are accompanied by an increase in cytokines, chemokines, and other SASP proteins. These phenotypic changes culminate in inflammation, fibrosis, loss of regenerative capacity, and ultimately tissue degeneration13. Recently, we analyzed AcanCreERT2;p16Ink4a conditional knockout mice and found decreased levels of cell death, SASP, and aberrant matrix changes in the discs of aged mice11. This finding is supported by reduced oxidative stress and disc degeneration in Cdkn2a germline knockout mice in response to a tail suspension injury model14. Additionally, Patil et al.10 used genetically engineered p16-3MR transgenic mice to demonstrate that systemic clearance of p16INK4a-positive cells mitigated age-related disc degeneration by reducing matrix catabolism and senescent cells in the disc compartment. Similarly, Cherif et al.15,16 showed effective clearing of senescent disc cells and reduction in inflammatory signaling using senolytics RG-7112 and o-Vanillin in ex vivo and in vitro assay systems. While these studies implicate senescent cells in driving disc pathology, it remains to be established if senolytic drugs can slow, cure, or even prevent disc degeneration during physiological aging in vivo. The concept of senolytic therapy is that apoptosis can be selectively initiated in senescent cells by inhibiting the pro-survival mechanisms upregulated during senescence. Zhu et al.17 first demonstrated this concept by suppressing the pro-survival BCL-XL and EFNB1 pathways that are highly activated by senescent cells, and other senolytic targets have emerged18–20. Of note, the combination of Dasatinib (D)—a Src/tyrosine kinase inhibitor—and Quercetin (Q)—a natural flavonoid that binds to BCL-2 and modulates transcription factors, cell cycle proteins, pro- and anti-apoptotic proteins, growth factors and protein kinases21,22—has been used extensively as a senolytic. The D + Q combination has shown beneficial effects in idiopathic pulmonary fibrosis23, bone loss24, and improved physical condition and lifespan25. In recent human clinical trials, D + Q reduced the number of senescent cells and improved physical performance26,27. Cognizant of these results, we investigated the therapeutic potential of D + Q in the context of disc degeneration. Accordingly, we treated wild-type C57BL/6 (BL6) mice beginning at: 6 months—to prevent disc degeneration onset (skeletally mature mice with healthy discs); 14 months—to bar progression of disc degeneration (middle-aged mice with early signs of degeneration); and 18 months—to rescue established disc degeneration (elderly mice with visible degeneration) up to 23 months of age. Our results show that there is a time-dependent effect of the D + Q senolytic cocktail on restoring disc health. This work provides important in vivo evidence that D + Q can, in a non-invasive manner, target senescent cells and mitigate the effects of age-dependent disc degeneration. RESULTS Dasatinib and Quercetin treatment alleviates age-dependent intervertebral disc degeneration and decreases senescence burden Senescence plays an essential role in intervertebral disc aging pathology and disease progression10,11,14. To date, no pharmacological approaches to prevent age-related disc degeneration exist. We treated 6-, 14-, and 18-month-old wild-type C57BL/6 (BL6) mice up to 23 months (6–23 M, 14–23 M, 18–23 M), with a weekly injection of a Dasatinib (D) and Quercetin (Q) combination to target senescent cells and prevent and/or treat age-related disc degeneration (Fig. 1a). Histological analysis of lumbar discs from 6–23 M and 14–23 M D + Q cohorts showed better preservation of tissue and cell morphology, with maintenance of NP/AF compartment demarcation and the NP cell band and a lower number of AF clefts relative to Vehicle-treated control animals (Veh) (Fig. 1b and Supplementary Fig. 1a). By contrast, mice in 18–23 M cohort did not show any significant improvements in disc morphology relative to the Veh group (Supplementary Fig. 1b). Histological grades of degeneration for lumbar levels were recorded using a modified Thompson grading system28,29. Grade distributions as well as combined average grades showed lower scores of degeneration in the NP and AF compartments of 6–23 M and 14–23 M D + Q cohorts in comparison to respective Veh groups (Fig. 1c, d). Level-by-level analysis of NP degeneration scores showed significantly lower grades in L4-5 and L5-6 in 6–23 M and 14–23 M D + Q mice, respectively, trending toward lower grades at other levels (Fig. 1e and Supplementary